Triple-positive profile may flag adverse prostate cancer pathology
Overview
A combination of prostate-specific antigen density, multiparametric MRI, and PSMA PET/CT findings may identify a subgroup of prostate cancer patients at risk for adverse pathology. In a study of 413 patients, those meeting all three criteria had a 100% positive predictive value for adverse pathology.
Background
Prostate cancer remains a significant health concern, being the second leading cause of cancer-related deaths among men in the United States. Accurate identification of patients at risk for aggressive disease is crucial for guiding treatment decisions. The integration of advanced imaging techniques with clinical parameters may enhance diagnostic accuracy and inform biopsy strategies.
Data Highlights
| Parameter | Adverse Pathology Rate |
|---|---|
| PSAD ≤ 0.15 | 48% |
| PSAD > 0.15 | 72% |
| PI-RADS 3 or lower | 45% |
| PI-RADS 4 | 52% |
| PI-RADS 5 | 80% |
| PRIMARY 1 to 4 | 55% |
| PRIMARY 5 | 85% |
Key Findings
- 60% of patients had adverse pathology at radical prostatectomy.
- Adverse pathology rates increased with higher PSAD and PI-RADS scores.
- Age, PSAD, PI-RADS 5, and PRIMARY 5 were independently associated with adverse pathology.
- The combined model of clinical and imaging predictors showed greater discrimination for adverse pathology than individual parameters.
- All patients with PSAD > 0.15, PI-RADS 5, and PRIMARY 5 had adverse pathology.
- The triple-positive profile had 100% specificity and positive predictive value, but low sensitivity (9%).
Clinical Implications
The findings indicate that combining PSAD, mpMRI, and PSMA PET/CT may help identify patients at risk for adverse pathology.
Conclusion
The study highlights the potential of a triple-positive profile in identifying patients with adverse prostate cancer pathology.
Related Resources & Content
- European Urology Open Science, 2024 -- Triple-positive profile may flag adverse prostate cancer pathology
- the pathologist — Treat or Surveil
- Urinary PCA3 Molecular Assay for Prostate Cancer: Correlation with Pathological Characteristics and Influence of Collection Methods
- Tailoring Prostate Cancer Diagnosis through Multivariate Risk Assessment: The Role of MRI in Clinical Practice
- the pathologist — Giving Prostate Cancer the Third Degree
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer 2026
- PRIMARY2 Trial Results
- https://pubmed.ncbi.nlm.nih.gov/41318235/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
